Enriched enrollment randomized double-blind placebo-controlled cross-over trial with phenytoin cream in painful chronic idiopathic axonal polyneuropathy (EPHENE): a study protocol

David J Kopsky, Ruben P A van Eijk, Janna K Warendorf, Jan M Keppel Hesselink, Nicolette C Notermans, Alexander F J E Vrancken, David J Kopsky, Ruben P A van Eijk, Janna K Warendorf, Jan M Keppel Hesselink, Nicolette C Notermans, Alexander F J E Vrancken

Abstract

Background: Patients with chronic idiopathic axonal polyneuropathy (CIAP) can have neuropathic pain that significantly impacts quality of life. Oral neuropathic pain medication often has insufficient pain relief and side effects. Topical phenytoin cream could circumvent these limitations. The primary objectives of this trial are to evaluate (1) efficacy in pain reduction and (2) safety of phenytoin cream in patients with painful CIAP. The main secondary objective is to explore the usefulness of a double-blind placebo-controlled response test (DOBRET) to identify responders to sustained pain relief with phenytoin cream.

Methods: This 6-week, enriched enrollment randomized double-blind, placebo-controlled triple cross-over trial compares phenytoin 20%, 10% and placebo cream in 48 participants with painful CIAP. Enriched enrollment is based on a positive DOBRET in 48 participants who experience within 30 minutes ≥2 points pain reduction on the 11-point numerical rating scale (NRS) in the phenytoin 10% cream applied area and ≥1 point difference in pain reduction on the NRS between phenytoin 10% and placebo cream applied area, in favour of the former. To explore whether DOBRET has predictive value for sustained pain relief, 24 DOBRET-negative participants will be included. An open-label extension phase is offered with phenytoin 20% cream for up to one year, to study long-term safety. The main inclusion criteria are a diagnosis of CIAP and symmetrical neuropathic pain with a mean weekly pain score of ≥4 and <10 on the NRS. The primary outcome is the mean difference between phenytoin 20% versus placebo cream in 7-day average pain intensity, as measured by the NRS, over week 2 in DOBRET positive participants. Key secondary outcomes include the mean difference in pain intensity between phenytoin 10% and phenytoin 20% cream, and between phenytoin 10% and placebo cream. Furthermore, differences between the 3 interventions will be evaluated on the Neuropathic Pain Symptom Inventory, EuroQol EQ5-5D-5L, and evaluation of adverse events.

Discussion: This study will provide evidence on the efficacy and safety of phenytoin cream in patients with painful CIAP and will give insight into the usefulness of DOBRET as a way of personalized medicine to identify responders to sustained pain relief with phenytoin cream.

Trial registration: ClinicalTrials.gov NCT04647877 . Registered on 1 December 2020.

Keywords: CIAP; Cream; Cross-over trial; Cryptogenic Polyneuropathy; Idiopathic polyneuropathy; Neuropathic pain; Phenytoin; Polyneuropathy; Randomized study; Topical.

Conflict of interest statement

DJK and JMKH are holders of two patent applications: Topical phenytoin for use in the treatment of peripheral neuropathic pain (WO2018106107); and Topical pharmaceutical composition containing phenytoin and a (co-)analgesic for the treatment of chronic pain (WO2018106108).

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flow chart. DB, double-blind; DOBRET, double-blind placebo-controlled response test
Fig. 2
Fig. 2
Finger Tip Unit

References

    1. Warendorf J, Vrancken AF, van Schaik IN, Hughes RA, Notermans NC. Drug therapy for chronic idiopathic axonal polyneuropathy. Cochrane Database Syst Rev. 2017;6(6):Cd003456.
    1. Erdmann PG, van Genderen FR, Teunissen LL, Notermans NC, Lindeman E, van Wijck AJ, et al. Pain in patients with chronic idiopathic axonal polyneuropathy. Eur Neurol. 2010;64(1):58–64.
    1. Poliakov I, Toth C. The impact of pain in patients with polyneuropathy. Eur J Pain. 2011;15(10):1015–1022.
    1. Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: prevalence of pain and impact on quality of life. Brain Behav. 2019;9(1):e01171.
    1. Lindh J, Tondel M, Osterberg A, Vrethem M. Cryptogenic polyneuropathy: clinical and neurophysiological findings. J Peripher Nerv Syst. 2005;10(1):31–37.
    1. Di Stefano G, Di Lionardo A, Di Pietro G, Cruccu G, Truini A. Pharmacotherapeutic options for managing neuropathic pain: a systematic review and meta-analysis. Pain Res Manag. 2021;2021:6656863.
    1. Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther. 2021;10(1):55–68.
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.
    1. Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology. 2022;98(1):31–43.
    1. Ney JP, Devine EB, Watanabe JH, Sullivan SD. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med. 2013;14(5):706–719.
    1. Reisner L. Pharmacological management of persistent pain in older persons. J Pain. 2011;12(3 Suppl 1):001.
    1. Keppel Hesselink JM, Kopsky DJ, Bhaskar AK. Skin matters! The role of keratinocytes in nociception: a rational argument for the development of topical analgesics. J Pain Res. 2016;10:1–8.
    1. Peppin JF, Albrecht PJ, Argoff C, Gustorff B, Pappagallo M, Rice FL, et al. Skin matters: a review of topical treatments for chronic pain. Part two: treatments and applications. Pain Ther. 2015;4(1):17–32.
    1. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;13(1):CD007393.
    1. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;24(7):CD010958.
    1. Mick G, Baron R, Finnerup NB, Hans G, Kern KU, Brett B, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2(1):71–77.
    1. Kopsky DJ, Keppel Hesselink JM. Topical phenytoin for the treatment of neuropathic pain. J Pain Res. 2017;10:469–473.
    1. Keppel Hesselink JM, Kopsky DJ. Phenytoin: a newly identified topical analgesic and its putative mechanisms of action: 2 case reports. J Pain Relief. 2017;6:284.
    1. Kopsky DJ, Keppel Hesselink JM. Phenytoin cream for the treatment of neuropathic pain: case series. Pharmaceuticals. 2018;11(2):53.
    1. Kopsky DJ, Keppel Hesselink JM. Single-blind placebo-controlled response test with phenytoin 10% cream in neuropathic pain patients. Pharmaceuticals. 2018;11(4):122.
    1. Kopsky DJ, Vrancken AFJE, van Eijk RPA, Notermans NC. Usefulness of a double-blind placebo-controlled response test to demonstrate rapid onset analgesia with phenytoin 10% cream in polyneuropathy. J Pain Res. 2020;13:877–882.
    1. Russell AL, Kopsky DJ, Hesselink JMK. Phenytoin cream for the treatment of sciatic pain: clinical effects and theoretical considerations: case report. J Pain Palliat Care Pharmacother. 2020;34(2):99–105.
    1. Kopsky DJ, Keppel Hesselink JM, Russell AL, Vrancken AFJE. No detectable phenytoin plasma levels after topical phenytoin cream application in chronic pain: inferences for mechanisms of action. J Pain Res. 2022;15:377–383.
    1. Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–1823.
    1. Visser NA, Vrancken AF, van der Schouw YT, van den Berg LH, Notermans NC. Chronic idiopathic axonal polyneuropathy is associated with the metabolic syndrome. Diabetes Care. 2013;36(4):817–822.
    1. VanDenKerkhof EG, Stitt L, Clark AJ, Gordon A, Lynch M, Morley-Forster PK, et al. Sensitivity of the DN4 in screening for neuropathic pain syndromes. Clin J Pain. 2018;34(1):30–36.
    1. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004;108(3):248–257.
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121.
    1. Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D, et al. Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI) J Pain Symptom Manage. 2011;41(3):558–565.
    1. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021;30(3):647–673.
    1. Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14–27.
    1. Lui KJ. Sample size determination for a 3-treatment 3-period crossover trial in frequency data. Ther Innov Regul Sci. 2018;52(4):407–415.
    1. Castor EDC . Castor electronic data capture 2019. 2019.
    1. Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther. 2006;109(1-2):57–77.
    1. Zhao P, Barr TP, Hou Q, Dib-Hajj SD, Black JA, Albrecht PJ, et al. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain. 2008;139(1):90–105.
    1. Seifert F, Maihöfner C. Central mechanisms of experimental and chronic neuropathic pain: findings from functional imaging studies. Cell Mol Life Sci. 2009;66(3):375–390.
    1. Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012;22(6):466–470.
    1. Patejdl R, Leroux AC, Noack T. Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil. 2015;27(10):1453–1465.
    1. Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol. 1995;47(6):1189–1196.
    1. Wang Y, Jones PJ, Batts TW, Landry V, Patel MK, Brown ML. Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore. Bioorg Med Chem. 2009;17(19):7064–7072.
    1. Kocot-Kępska M, Zajączkowska R, Mika J, Kopsky DJ, Wordliczek J, Dobrogowski J, et al. Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain-narrative review. Pharmaceutics. 2021;13(4):450.
    1. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–169.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться